Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on August 6, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report its second quarter 2026 financial results.
Rhea-AI Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) will host a conference call and webcast on August 6, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report its second quarter 2026 financial results.
According to Corvus Pharmaceuticals, domestic investors can join by dialing 1-800-717-1738, while international participants can use 1-646-307-1865 or an instant telephone access link. The live webcast will be available through the investor relations section of the company’s website, with a replay accessible for 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CRVS
In the Jul 31 session, CRVS gained 0.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Reporting date
- August 6, 2026
- Second quarter 2026 financial results and business update
- Conference call time
- 4:30 pm ET / 1:30 pm PT
- August 6, 2026
- Replay availability
- 90 days
- Webcast replay on Corvus' website
Previous Earnings date Reports
-
Scheduled fourth-quarter and full-year 2025 financial results conference call
-
Scheduled third-quarter 2025 financial results and business update
-
Scheduled second-quarter 2025 financial results conference call
-
Scheduled fourth-quarter and full-year 2024 financial results announcement
-
Scheduled third-quarter 2024 financial results conference call
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2026 financial results.
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 2 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Julia Stern
Real Chemistry
+1-763-350-5223
jstern@realchemistry.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.